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Melanoma accounts for the majority of deaths from skin cancer. Women tend to be diagnosed at a younger age
and have better survival than men. A tumor–host interaction might be responsible for these gender-specific
differences. Recently, a functional single-nucleotide polymorphism in the promoter of the human homolog of
mouse double minute 2 (MDM2) gene was characterized: single-nucleotide polymorphism (SNP)309 increases
the MDM2 transcription. In melanoma, the effects for SNP309 and the related tumor protein p53 (TP53) Arg72Pro
are inconsistent among published reports. This study investigated the association between SNP309 (RefSNP
accession ID (rs)2279744) and TP53 codon 72 (rs1042522) polymorphisms, with outcome in a hospital-based
cohort of 990 patients with melanoma. We assessed whether these polymorphisms were associated with
clinicopathological and phenotypic characteristics and whether these SNPs affect the age of onset of the
disease, recurrence, and survival. No significant associations were found between the SNPs and survival.
However, women carrying the SNP309 GG genotype were less likely to be diagnosed at a younger age: odds
ratioadjustedo50 0.52 (0.29–0.92). Our results suggest that women carrying the SNP309 GG genotype might be
at lower risk of developing melanoma at a younger age compared with those carrying TG or TT. Further studies
are needed to determine whether a nearby functional polymorphism is responsible for this effect in
premenopausal women.
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INTRODUCTION
Melanoma incidence continues to rise and accounts for the
great majority of deaths from skin cancer, with an estimated
8,700 deaths in 2010 (Jemal et al., 2010). The incidence of
melanoma is higher among women during the reproductive
years, but after the age of 50 years this cancer is more
frequent among men (Horner et al., 2009). Although women
tend to be diagnosed at an earlier age, they have better
survival than men (de Vries et al., 2008; Jemal et al., 2010).
Factors other than stage at diagnosis and body site seem to be
responsible for these gender differences, and a tumor–host
interaction has been proposed (de Vries et al., 2008;
Lasithiotakis et al., 2008; Joosse et al., 2011).
A frequent single-nucleotide polymorphism (SNP) in the
human homolog of mouse double minute 2 (MDM2) gene,
commonly referred to as SNP309, was found to be a genetic
risk modifier of cancer incidence in individuals with the
Li–Fraumeni syndrome (Bond et al., 2004). The SNP consists
of a T to G change, and the authors proposed that the G allele
favors the binding of the specific protein 1 transcription
factor, which results in elevated levels of MDM2 mRNA and
protein, thereby attenuating the p53 response. In addition, it
has been proposed that SNP309 regulates MDM2 expression
through enhanced binding of the specific protein 1 transcrip-
tion factor and estrogen receptor (Okumura et al., 2002;
Kinyamu and Archer, 2003; Bond et al., 2006a). Some
studies, but not all, reported that the MDM2 SNP309 might
modify the risk, age of onset, or prognosis in a variety of
cancers (Alhopuro et al., 2005; Bond et al., 2006b; Schmidt
et al., 2007; Wilkening et al., 2007; Krekac et al., 2008; Fang
et al., 2010; Yu et al., 2011). In melanoma, there are only a
few investigations on MDM2 SNP309 to date, and the
reported effect for this SNP is not consistent between studies:
one study found an association between SNP309 and risk for
melanoma, as well as age at diagnosis, and other studies
found no effect on either risk, age at diagnosis, or progression
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Similarly, the effect of a second widely studied poly-
morphism in the Mdm2–p53 pathway varies across different
studies. The TP53 polymorphism on codon 72 consists of a
G-to-C transition that results in the substitution of arginine
(Arg) to proline (Pro) (Matlashewski et al., 1987). It has been
proposed that the status of codon 72 can influence the
biological behavior of some p53 mutants (Marin et al., 2000).
The allelic variants exhibit distinct structural features and
biological properties, with the codon 72 Pro being credited
with a more efficient transcriptional activation and suppres-
sion of cell growth, and the arginine with a less efficient
induction of apoptosis (Thomas et al., 1999). With regard
to melanoma, two epidemiological studies reported an
increased risk associated with the genotype Arg/Arg (Shen
et al., 2003; Li et al., 2008), two studies found an association
with the genotype Pro/Pro (Gwosdz et al., 2006; Stefanaki
et al., 2007), and other studies found no effect with the
development or progression of melanoma (Povey et al.,
2007; Firoz et al., 2009). Some of the inconsistencies found
across the different studies may be due to differences in
sample size, study design, or characteristics of the study
subjects.
In this hospital-based study, we genotyped the TP53
codon 72 (G4C, RefSNP accession ID (rs)1042522) and the
MDM2 SNP309 (T4G, rs2279744) polymorphisms in a cohort
of 990 individuals with melanoma and assessed whether
these polymorphisms are associated with the patients’ clinical,
pathological, and phenotypic characteristics and whether
these SNPs affect the age of onset of the disease, recurrence,
and survival.
RESULTS
The characteristics of the study participants are described in
Table 1. In all, 96% were non-Hispanic white and 4% were
Hispanic, non-Hispanic black, and Asian/Indian. We found
that women were diagnosed 7 years (median) earlier than
men, tended to have lighter skin, and their tumors were
diagnosed at lower stages, with smaller Breslow thickness
values and lower Clark level. Furthermore, their melanomas
occurred on the extremities more often than in men. Age at
diagnosis, thickness, stage at diagnosis, phenotypic index,
and anatomic site were significantly associated with
gender after correcting for multiple testing. There were
195 deaths, including 113 disease-specific deaths, and 285
recurrences. The mean follow-up for the survivors was
6 years. The genotype and allele frequencies are shown
in Table 2.
Effect ofMDM2 and TP53 genotypes on recurrence and survival
MDM2 SNP309 G allele did not have a significant effect on
the risk of death of melanoma or on disease recurrence, after
adjusting for covariates (Tables 3 and Supplementary Table
S1 online). The results were similar when the analysis was
restricted to non-Hispanic whites. We did not find any
significant associations between Arg72Pro (G4C, rs1042522)
and disease recurrence or survival (Table 3).
Table 1. Characteristics of the study participants
Total,
N (%)
Women,
N (%)
Men,
N (%) P-value1
Total cases 990 (100) 421 (42.5) 569 (57.5)
Age at diagnosis
(median years and range)
55.2 (5–89) 50.1 (5–88) 57.2 (10–89) o0.01
Race 0.89
Non-Hispanic white 951 (96.1) 404 (95.9) 547 (96.1)
Other2 39 (3.9) 17 (4.1) 22 (3.9)
Breslow thickness
(median, mm)
1.5 1.2 1.5 o0.01
Stage at diagnosis 0.01
0 69 (7.0) 34 (8.2) 35 (6.2)
I 492 (49.7) 227 (54.4) 265 (47.2)
II 219 (22.2) 90 (21.6) 129 (22.9)
XIII 199 (20.1) 66 (15.8) 133 (23.7)
Missing 11 (1.1)
Clark level 0.04
I 58 (5.9) 30 (8.0) 28 (5.6)
II 106 (10.7) 51 (13.6) 55 (11.0)
III 150 (15.2) 72 (19.3) 78 (15.6)
IV 490 (49.5) 200 (53.5) 290 (58.2)
V 69 (7.0) 21 (5.6) 48 (9.6)
Missing 117 (11.8)
Multiple primary melanoma 175 (17.7) 70 (16.6) 105 (18.5) 0.45
Family history of melanoma 175 (17.7) 83 (19.7) 92 (16.2) 0.15
Phenotypic index3 0.02
1 107 (10.8) 48 (11.7) 59 (10.6)
2 194 (19.6) 79 (19.2) 115 (20.7)
3 366 (37.0) 138 (32.6) 228 (41.1)
4 222 (22.4) 102 (24.8) 120 (21.6)
5 78 (7.9) 44 (10.7) 34 (6.1)
Missing 23 (2.3)
Nevi 0.84
None 259 (26.2) 105 (26.1) 154 (27.8)
Few 492 (49.7) 211 (52.4) 281 (50.6)
Moderate 167 (16.9) 72 (17.9) 95 (17.1)
Many 40 (4.0) 15 (3.7) 25 (3.7)
Missing 32 (3.2)
Anatomic site o0.01
Head/face 72 (7.3) 18 (4.3) 54 (9.5)
Trunk 339 (34.2) 101 (24.0) 238 (41.8)
Extremity 537 (54.2) 286 (67.9) 251 (44.1)
Unknown 42 (4.2) 16 (3.8) 26 (4.6)
1P-values were calculated with w2 test for gender; significant P-values
(p0.05) appear in bold type.
2Hispanic, black non-Hispanic, and Asian/Indian.
3Defined in the Materials and Methods section.
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Effect of MDM2 and TP53 genotypes on clinicopathological
and phenotypic features
It has been proposed that the effect of the SNP309 occurs in a
gender-specific and hormone-dependent manner. Therefore,
we conducted a stratified analysis by gender and age. We
found that women carrying one or two Gs were diagnosed at
an older age (mean: 51.7 and 54.3 years old; median: 50.1
and 57.6 years old, respectively) than those carrying two Ts
(mean: 48.3 years old; median 48.6 years old), and that this
difference is significant (P¼0.03) (Table 4), although not
when the P-value is adjusted for multiple comparisons. When
stratified by decade of age, this difference was of borderline
significance (Supplementary Table S2 online). Figure 1a
shows the distribution of age at diagnosis by SNP309 geno-
type for men and women. We then calculated the odds ratios
(OR) and 95% confidence intervals (95% CI) using logistic
regression. For these analyses, we dichotomized the variable
‘‘age at diagnosis’’. We used varying age cutoffs in order to
calculate the odds of being diagnosed with melanoma by a
certain specified age for patients carrying the SNP309 GG
compared with TG or TT genotypes (Table 5). In univariate
analysis, we found that women homozygous for the G allele
are at lower risk of developing melanoma within the o50 and
o60 age groups. After adjusting for tumor thickness, stage,
and family history, the GG genotype appeared protective in
younger women (ORo50vs.450 0.60, 95% CI 0.35–1.00,
P¼0.05; Table 5). Very similar results were obtained when
analysis was restricted to white Caucasians (ORo60vs.460
0.53, 95% CI 0.31–0.90, P¼ 0.02), and when we excluded
those with in situ lesions (ORo60vs.460 0.55, 95% CI
0.31–0.94, P¼ 0.03). The results remained statistically
significant after including phenotypic index and moles in
the model (ORo50vs.450 0.52, 95% CI 0.29–0.92, P¼0.02;
Table 5), and after correcting for multiple testing (P¼0.05).
We did not see the same effect among men.
We did not find any associations between Arg72Pro (G4C,
rs1042522) and patients’ clinicopathological or phenotypic
characteristics (Supplementary Table S3 online and Figure 1b).
We also combined the two polymorphisms, MDM2 SNP309
and TP53 codon 72, and found no significant differences in
the distribution of TP53 genotypes according toMDM2 geno-
types in either women or men (data not shown).
DISCUSSION
This study evaluated the associations between the polymor-
phisms MDM2 SNP309 T4G and TP53 codon 72 Arg4Pro
on the clinicopathological and phenotypic characteristics,
age of onset, recurrence, and survival in a cohort of 990
patients with melanoma. This study does not support the GG
genotype as a risk factor for early onset of melanoma in
women. Our results suggest that women carrying the GG
genotype might be at a lower risk of developing melanoma
under the age of 60 years than those carrying TG or TT.
The rate of somatic TP53 mutations in melanoma is very
low; however, p53 has a central role in pigmentation and
tanning response, and there is a myriad of mechanisms by
which this tumor suppressor’s pathway may be deregulated
in tumors (Box and Terzian, 2008). Thus, several studies
investigated the association between tumor features and the
only known common non-synonymous SNP in TP53 (codon
72); however, the results are still controversial. With regard to
melanoma, Li et al. (2008), in an extension of their initial
investigation (Shen et al., 2003), found a positive association
between the GG (Arg/Arg) genotypes and risk, whereas two
other studies found an increased risk of melanoma for carriers
of the codon 72 CC genotype (Pro/Pro). These differences
can be attributed to the sample size and to ethnic differ-
ences across the studied subjects (Stefanaki et al., 2007).
We found no evidence for an effect of the TP53 codon
72 SNP in relation to clinicopathological characteristics, age
of onset, or to recurrence. Our results support previous
findings (Han et al., 2006; Povey et al., 2007; Firoz et al.,
2009; Jiang et al., 2011).
MDM2, the other key factor of the TP53 pathway, is over-
expressed in many cancers; and mouse models that over-
express MDM2 are more susceptible to cancer development
(Jones et al., 1998). In humans, overexpression of MDM2 has
been described in the absence of genetic amplification in
invasive and metastatic melanomas (Polsky et al., 2001), and
in association with disease-free survival (relative risk: 0.47;
95% CI: 0.24–0.89) and overall survival (relative risk: 0.55;
95% CI: 0.33–0.94) (Polsky et al., 2002). These findings were
confirmed in a large study of 405 melanomas in which the
Table 2. TP53 codon 72 (Arg/Pro) andMDM2 SNP309
genotype and allele distributions
Reported
frequency (%)1,2
Total,
N (%)
Women,
N (%)
Men,
N (%)
MDM2 SNP309 (rs2279744)
TT 36.5–45.7 360 (36.5) 147 (35.2) 213 (37.5)
TG 41.8–47.5 451 (45.7) 194 (46.4) 257 (45.2)
GG 12.2–19.2 175 (17.8) 77 (18.4) 98 (17.3)
T 61.8–63.4 1,171 (59.4) 488 (58.4) 683 (60.1)
G 36.6–38.2 801 (40.6) 348 (41.6) 453 (39.9)
Total 986 (100) 418 (100) 568 (100)
TP53 c.72 (rs1042522)
GG (Arg/Arg) 58–62 524 (54.0) 220 (53.3) 304 (54.5)
GC (Arg/Pro) 29–30 374 (38.5) 164 (39.7) 210 (37.6)
CC (Pro/Pro) 8.3–12.9 73 (7.5) 29 (7.0) 44 (7.9)
G (Arg) 77 1,422 (73.2) 604 (73.1) 818 (73.3)
C (Pro) 23 520 (26.8) 222 (26.9) 298 (26.7)
Total 971 (100) 413 (100) 558 (100)
Abbreviations: Arg, arginine; dbSNP, single-nucleotide polymorphism
database; MDM2, human homolog of mouse double minute 2; Pro,
proline; rs, RefSNP accession ID; TP53, tumor protein p53.
1Genotype and allelic frequencies obtained for TP53 codon 72 (rs1042522)
in dbSNP, accessed in January 2011 (Caucasian and HapMap-Caucasian
male).
2Frequencies for MDM2 SNP309 (rs2279744) are not available in dbSNP
and represent a range of those reported in cancer-free controls from the
United Kingdom, United States, and Italy (Schmidt et al., 2007; Ellis et al.,
2008; Nan et al., 2009; Capasso et al., 2010).
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authors found higher levels of nuclear MDM2 expression in
primary than in metastatic melanomas (Berger et al., 2004).
The precise beneficial effect of MDM2 is still not well
understood, but may involve a p53-independent cell cycle
arrest and inhibition of cell proliferation (Brown et al., 1998;
Deb, 2003; Berger et al., 2004).
Several polymorphisms have been identified within MDM2,
but the SNP309 T4G SNP at a regulatory site in intron 1 has
been the most studied. In the presence of the G allele, the
coactivator of the estrogen receptor specific protein 1 trans-
cription factor binds to MDM2 more efficiently than when
the T allele is present (Bond et al., 2004). This led to the
hypothesis that individuals carrying the G allele would exhibit
higher levels of MDM2, especially in the presence of estro-
gens, with the subsequent reduction of tumor-suppressing
function of p53 (Bond et al., 2006a). In our study, we did
not find statistically significant associations between the
MDM2 SNP309 T4G polymorphism and clinicopathological
variables. However, when we stratified the groups into
gender and decades of age at diagnosis, we found an
increased frequency of the GG genotype among women
diagnosed at an older age, which does not support the
hypothesis of an active estrogen signaling via the SNP309 GG
genotype. Another study conducted in 249 cases and 291
controls found that women having the SNP309 GG genotype
were diagnosed at an older age, although the association did
not reach statistical significance (Capasso et al., 2010). The
same authors found a positive association between the
GG genotype and tumor thickness (Capasso et al., 2010).
Nan et al. (2009) conducted a nested case–control study of
the Nurses’ Health Study among 219 cases and found no
associations between SNP309 and risk or age of onset.
They also tested 3,207 women pooled from controls of three
nested case–control studies within the Nurses’ Health Study
and found that the G allele was inversely associated with
the number of moles on the arm (adjusted OR: 0.68;
95% CI: 0.53–0.87 for GG vs. TT) and an increased tendency
for childhood tanning (adjusted OR: 1.30; 95% CI:
1.01–1.68).
SNP309 G allele has been proposed to mediate the
increase in MDM2 mRNA and protein levels. In our study, we
found a non-statistically reduced OR in relation to melanoma
death. We cannot speculate on the basis of our results that
increased levels of MDM2 might be associated with better
survival. However, interestingly and as mentioned earlier,
overexpression of MDM2 in melanomas in the absence of
genetic amplification has indeed been reported in association
with better survival (Polsky et al., 2001).
Our results do not support the findings from Firoz et al.
(2009), who reported that among the 89 genotyped women,
carriers of the GG genotype were nearly 4-fold more likely to
be diagnosed at an early age compared with women with the
T allele (unadjusted OR: 3.89; 95% CI: 1.22–12.31). The
difference in our findings is likely because of the much larger
sample size (n¼ 990, including 421 women and 569 men),
which allowed us to adjust the analysis for potential con-
founders. In addition, our cohort included patients who were
younger, had thicker tumors, and were at higher stages of the
disease.
Collectively, the studies by Nan et al. (2009), Capasso
et al. (2010), and ours agree in that the MDM2 SNP309 G
does not appear to be a risk factor for developing melanoma
at a young age. A very recent report unveils a second MDM2
promoter SNP in position 285 (SNP285G4C), which forms
a distinct haplotype with SNP309 (SNP285C/SNP309G)
(Knappskog et al., 2011). Although the G allele of SNP309
enhances the transcription, the C allele of SNP285 has a
much stronger effect and reduces the binding of specific
protein 1 transcription factor on the promoter. Moreover,
SNP285C reduces the risk of both ovarian and breast cancer
(Knappskog et al., 2011). Consequently, although we cannot
rule out the influence of other modifying genes and/or
environmental factors that might be affecting the role of
MDM2 in melanoma, it will be important to consider a more
Table 3. Effect of MDM2 and TP53 genotypes on overall mortality, disease-specific mortality, and recurrence
Overall mortality Disease-specific mortality Recurrence
HR1 95% CI P-value HR1 95% CI P-value HR1 95% CI P-value
MDM2 SNP309 0.197 0.188 0.902
TT 1.00 1.00 1.00
TG 0.79 (0.56–1.12) 0.74 (0.47–1.15) 1.07 (0.80–1.43)
GG 0.68 (0.43–1.06) 0.59 (0.32–1.10) 1.04 (0.73–1.50)
TP53 c.72 0.290 0.131 0.421
GG 1.00 1.00 1.00
GC 0.76 (0.54–1.07) 0.62 (0.39–0.99) 0.83 (0.63–1.09)
CC 0.88 (0.49–1.60) 0.81 (0.38–1.74) 0.98 (0.61–1.59)
Abbreviations: CI, confidence interval; HR, hazard ratio; MDM2, human homolog of mouse double minute 2; SNP, single-nucleotide polymorphism; TP53,
tumor protein p53.
1Adjusted for age, gender, thickness, stage at diagnosis, and anatomic site.
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complex interaction with the haplotypes SNP285C/SNP309G
in future investigations. Considering the fact that the SNP285
appears to be a young SNP present among Western
Europeans but absent in Asians, it is interesting to note that
two meta-analyses found that the effect of SNP309 on cancer
risk is race specific, with SNP309 exerting its effect in Asians
but not in Caucasians, where SNP285 can oppose its function
(Gui et al., 2009; Economopoulos and Sergentanis, 2010).
Future studies are needed to determine whether SNP285C is
responsible for the delayed onset among women with
melanoma who carry SNP309 G alleles.
One limitation of this study is that we were not able to
statistically correct for population stratification because of a
lack of ancestry-informative markers in this cohort. However,
we conducted a separate analysis on self-identified non-Hispanic
whites, which has been shown to sufficiently reduce
population stratification bias in well-designed cancer cohort
studies (Wacholder et al., 2002). This is especially true
for case-only melanoma studies, where the non-white
population is a very small minority. Importantly, the results
obtained from this hospital cohort may not necessarily be
generalized for all melanomas. We believe, however, that
Table 4. Distribution of MDM2 SNP309 genotypes according to clinicopathological and phenotypic features
All (N=986) Women (N=418) Men (N=568)
TT
(N=360)
TG
(N=451)
GG
(N=175)
P-
value1
TT
(N=147)
TG
(N=194)
GG
(N=77)
P-
value1
TT
(N=213)
TG
(N=257)
GG
(N=98)
P-
value1
Age at diagnosis
(years), mean
(SD)
53.5 (15.6) 54.1 (15.0) 55.9 (16.6) 0.16 48.3 (15.8) 51.7 (16.5) 54.3 (17.7) 0.03 57.1 (14.4) 56.0 (13.6) 57.2 (15.7) 0.47
Tumor thickness
(mm), median
(IQR)
1.3 (0.7–2.5) 1.5 (0.9–2.7) 1.4 (0.8–2.5) 0.24 1.2 (0.7–2.1) 1.4 (0.7–2.2) 1.2 (0.7–2.1) 0.90 1.4 (0.7–2.6) 1.6 (0.9–3.4) 1.5 (0.8–2.8) 0.10
Stage at diagnosis 0.10 0.68 0.23
0 21 (30.4) 37 (53.6) 11 (15.9) 12 (35.3) 17 (50.0) 5 (14.7) 9 (25.7) 20 (57.1) 6 (17.1)
I 190 (38.9) 203 (41.5) 96 (19.6) 80 (35.6) 98 (43.6) 47 (20.9) 110 (41.7) 105 (39.8) 49 (18.6)
II 77 (35.3) 102 (46.8) 39 (17.9) 31 (34.8) 41 (45.1) 17 (19.1) 46 (35.7) 61 (47.3) 22 (17.1)
XIII 66 (33.2) 108 (54.3) 28 (14.1) 22 (33.3) 36 (54.6) 8 (12.1) 44 (37.1) 69 (51.9) 20 (15.0)
Anatomic site 0.10 0.65 0.15
Head/face 23 (31.9) 37 (51.4) 12 (16.7) 6 (33.3) 11 (61.1) 1 (5.6) 17 (31.5) 26 (48.2) 11 (20.4)
Trunk 138 (41.1) 136 (40.5) 62 (18.5) 39 (39.4) 41 (41.4) 19 (19.2) 99 (41.8) 95 (40.1) 43 (18.2)
Extremity 185 (34.5) 253 (47.2) 98 (18.3) 96 (33.7) 134 (47.0) 55 (19.3) 89 (33.5) 119 (47.4) 43 (17.1)
Unknown 14 (33.3) 25 (59.5) 3 (7.1) 6 (37.5) 8 (50.0) 2 (12.5) 8 (30.8) 17 (65.3) 1 (3.9)
Family history of
melanoma
67 (38.5) 77 (44.3) 30 (17.2) 0.80 29 (34.9) 35 (42.2) 19 (22.9) 0.49 38 (41.8) 42 (46.2) 11 (12.1) 0.35
Number of moles 0.20 0.57 0.11
None 89 (34.5) 121 (46.9) 48 (18.6) 39 (37.5) 46 (44.2) 19 (18.2) 50 (32.5) 75 (48.7) 29 (18.8)
Few 190 (38.6) 215 (43.7) 87 (17.7) 76 (36.0) 93 (44.1) 42 (19.9) 114 (40.6) 122 (43.4) 45 (16.0)
Moderate 63 (38.2) 74 (44.8) 28 (17.0) 21 (29.6) 38 (53.5) 12 (16.9) 42 (44.7) 36 (38.3) 16 (17.0)
Many 7 (17.5) 24 (60.0) 9 (22.5) 3 (20.0) 10 (66.7) 2 (13.3) 4 (16.0) 14 (56.0) 7 (28.0)
Phenotypic index 0.60 0.32 0.56
1 37 (34.6) 49 (45.8) 21 (19.6) 17 (35.4) 17 (35.4) 14 (29.2) 20 (33.9) 32 (54.2) 7 (11.9)
2 66 (34.2) 90 (46.6) 37 (19.2) 26 (32.9) 49 (50.6) 13 (16.5) 40 (35.1) 50 (43.9) 24 (21.1)
3 134 (36.6) 166 (45.4) 66 (18.0) 47 (34.1) 63 (45.6) 28 (20.3) 87 (38.2) 103 (45.2) 38 (16.7)
4 86 (39.3) 98 (44.7) 35 (16.0) 34 (34.4) 48 (48.5) 17 (17.2) 52 (43.3) 50 (41.7) 18 (15.0)
5 29 (37.2) 42 (53.8) 7 (9.0) 18 (40.9) 23 (52.3) 3 (6.8) 11 (32.4) 19 (55.6) 4 (11.8)
Abbreviations: IQR, interquartile range; MDM2, human homolog of mouse double minute 2; SD, standard deviation; SNP, single-nucleotide polymorphism;
TP53, tumor protein p53.
Note: numbers within parentheses represent row percent, except for genotype, age at diagnosis, and tumor thickness variables. Significant results appear in
bold type.
1P-values were calculated with the w2 test.
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there is a plausible biological explanation for our findings,
and that there are several strengths of our study, including its
prospective cohort design, which includes extensive patient
characteristics and follow-up of patient outcomes. More-
over, to the best of our knowledge, this study comprises
the largest number of melanoma cases tested for these
SNPs to date. The findings reported here need to be
replicated in an independent and larger study to rule out
competing influences of chance and population stratification
and to investigate the influence of the surrounding genetic
environment.
In summary, in this study we did not find an indication
for melanoma recurrence, survival, or an earlier age of onset
of melanoma in carriers of either MDM2 SNP309 or TP53
codon 72 Arg/Pro variant alleles. Our results suggest that
women carrying the SNP309 GG genotype might be at a
lower risk of developing melanoma at a young age compared
with those carrying TG or TT. It is possible to hypothesize
that our observations are the result of the antagonistic effect
of the nearby functional SNP; however, this remains to be
tested and corroborated in future studies. It is premature
to attribute clinical and public health usefulness of our
findings at this time; however, identifying host factors that
modify age of onset or outcomes could be informative in
individuals at risk.
MATERIALS AND METHODS
Study population
A total of 990 patients with cutaneous malignant melanoma (stages
0–IV) were recruited between February 2001 and August 2005 at
Memorial Sloan-Kettering Cancer Center (MSKCC), New York. The
study protocol was approved by the Memorial Sloan-Kettering Cancer
Center Institutional Review Board, and the study was conducted
according to the Declaration of Helsinki Principles. In all, 96% of the
eligible individuals agreed to participate in the study. All participants
signed an informed consent and research authorization. Patients
filled out a short, self-administered questionnaire that included
information on gender, race, age, family history, density of freckles,
hair color, eye color, propensity to burn, and ability to tan after sun
exposure. The information on hair and eye color, and propensity to
tan or sunburn were combined into a single variable, the phenotypic
index (Millikan et al., 2006). This phenotypic index represents the
sum of points assigned to hair color (brown/black: 1; light brown/
blond: 2; red/auburn: 3); eye color (brown: 0; green/hazel/blue: 1);
and propensity to tan (0) or to sunburn (1). We also obtained
information on dysplastic nevi, multiple primary melanomas, stage
at diagnosis and at follow-up (based on the American Joint
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Figure 1. Age at diagnosis in melanoma patients according to MDM2
SNP309 or TP53 Arg72Pro genotype and gender. The box plots display the
age distribution of melanoma diagnosis by gender for (a) MDM2 SNP309 and
(b) TP53 Arg72Pro. The boxes represent the interquartile range; the horizontal
thick line within each of the boxes represents the median age of diagnosis.
The dotted lines extend from the 1st quartile to the smallest non-outlier value
and from the 3rd quartile to the maximum non-outlier. Outliers are indicated
by open circles. The number of melanoma patients is indicated for each
genotype. Note the higher median age at diagnosis among the women carriers
of the SNP309 G allele. Arg, arginine; MDM2, human homolog of mouse
double minute 2; Pro, proline; SNP, single-nucleotide polymorphism; TP53,
tumor protein p53.
Table 5. ORs for age of onset of melanoma for carriers of the MDM2 SNP309 GG genotype
Age category N OR (95% CI)1 P-value ORadj (95% CI)
1,2 P-value ORadj (95% CI)
1,3 P-value
Women (total N=418)
o50 vs. X50 207 vs. 211 0.60 (0.35–0.98) 0.04 0.60 (0.35–1.00) 0.05 0.52 (0.29–0.92) 0.02
o60 vs. X60 282 vs. 136 0.51 (0.31–0.84) o0.01 0.47 (0.29–0.84) o0.01 0.42 (0.24–0.75) o0.01
Men (total N=568)
o50 vs. X50 184 vs. 384 0.90 (0.56–1.45) 0.67 0.97 (0.59–1.60) 0.91 0.90 (0.53–1.53) 0.71
o60 vs. X60 319 vs. 249 0.81 (0.52–1.26) 0.36 0.91 (0.57–1.43) 0.67 0.91 (0.55–1.48) 0.69
Abbreviations: CI, confidence interval; MDM2, human homolog of mouse double minute 2; OR, odds ratio; SNP, single-nucleotide polymorphism.
1Crude ORs were calculated for carriers of GG compared to those with GT or TT.
2ORadj, OR adjusted for stage at diagnosis, Breslow thickness, and family history.
3ORadj, OR adjusted for stage at diagnosis, Breslow thickness, family history, phenotypic index, and nevi.
1476 Journal of Investigative Dermatology (2012), Volume 132
J Cotignola et al.
MDM2 and TP53 SNPs in Melanoma Patients
Committee on Cancer 2002 classification), disease status, disease
recurrence, and survival. The characteristics of the study group are
shown in Table 1.
Biospecimens
Germline DNA was extracted from buccal cells (N¼ 990) using
Puregene kits (Gentra Systems, Minneapolis, MN) following the
manufacturer’s recommendations. DNA concentration and quality
were measured at 260 and 280nm in a SpectramaxPlus 384
(Molecular Devices, Sunnyvale, CA).
Genotyping
We genotyped samples for theMDM2 SNP309 (rs2279744; g.31345886
T4G) and the TP53 Arg72Pro (rs1042522; g.7176821G4C) poly-
morphisms using PCR-based methods. For the MDM2 SNP309,
genotyping was carried out by pyrosequencing (Ronaghi, 2003) with
the PSQTM HS96A instrument (Biotage AB, Uppsala, Sweden). The
PCR reactions included 10–15 ng DNA, 200mM dNTP (Invitrogen,
Carlsbad, CA), 2mM MgCl2 (Applied Biosystems, Foster City, CA),
0.025U ml1 of Taq polymerase (Applied Biosystems), 1 reaction
buffer, and 1mM of each primer (forward: 50-GGGCTGCGGGGCC
GCT-30; reverse: 50-biotin-AGTGACCCGACAGGCACCT-30) (Invitro-
gen). Cycling included a step at 951C for 5minutes, followed by
45 cycles of 951C for 20 seconds, 551C for 20 seconds, 721C for
20 seconds, with a final step at 721C for 5minutes. The MDM2
sequencing primer (50-GGGCTGCGGGGCCGCT-30) (Invitrogen)
was added to the single-stranded DNA and nucleotides were dis-
pensed automatically.
For the TP53 polymorphism, genotyping was carried out by dif-
ferential melting temperature analysis (Bennett et al., 2003) coupled
to the LightTyper Instrument (Roche Applied Science, Indianapolis,
IN). Briefly, the PCR reactions contained 10–15 ng DNA, 200 mM
dNTP (Invitrogen), 3.25mM MgCl2 (Applied Biosystems), 0.025Uml
1
of Taq polymerase (Applied Biosystems), 1 reaction buffer, 0.04mM
forward primer: 50-ATGGATGATTTGATGCTGT-30, 0.6 mM reverse
primer: 50-CAGAATGCAAGAAGCCC-30 (Invitrogen), and 0.15mM of
labeled probes (anchor, 50-AGATGAAGCTCCCAGAATGCCAG-
fluorescein; sensor, 50-LCRed640-GCTGCTCCCCCCGTG-phosphate)
(Roche Applied Science). The cycling consisted of a denaturation at
951C for 5minutes, followed by 50 cycles at 951C for 30 seconds,
551C for 20 seconds, 721C for 30 seconds, with a final extension at
721C for 5minutes.
All genotyping included blanks and known internal positive
controls. Samples that failed to amplify were repeated. Samples with
results that departed from the expected profiles for wild type,
heterozygote, or variant were sequenced to confirm specificity. To
this effect, DNA was amplified in an independent PCR, purified, and
then 10 ng of the product sequenced in an ABI 3730-XLDNA
Analyzer (Applied Biosystems). Additional quality control assurance
consisted of 5% randomly repeated samples. Assays ‘‘passed’’ in the
absence of signal in the negative (blank) controls, in the presence of
the expected signal or profile for the known internal controls, and
when there was 100% agreement between two independent readers,
and between blinded repeats added for quality control. Genotyping
was successful in 99.6 and 98.1% of the samples for the MDM2
SNP309 (rs2279744) and the TP53 Arg72Pro (rs1042522) SNPs,
respectively. The genotypes for both SNPs were in Hardy–Weinberg
equilibrium.
Statistical analysis
w2 Tests and Wilcoxon rank-sum test were used to test for asso-
ciations between the following: (i) clinicopathological and pheno-
typic characteristics of the patients and gender; (ii) genotypes and
various clinical and epidemiological factors by gender, and between
the MDM2 and TP53 genotypes. Multivariable logistic regression,
adjusting for thickness, stage, family history, phenotypic index, and
nevi, was conducted to examine the effect of the MDM2 SNP309
GG genotype on age of melanoma diagnosis.
Overall survival and disease-specific survival were calculated
from the date of initial diagnosis of melanoma to date of death or last
follow-up. Time to recurrence was calculated from the date of initial
diagnosis to date of first recurrence. Overall survival, disease-
specific survival, and time to recurrence were estimated using
Kaplan–Meier methods. The effect of genotype on survival outcomes
was evaluated with the Cox proportional model after adjusting for
clinicopathological factors, including age at diagnosis, stage, thickness,
gender, and site, and were selected a priori based on published
reports (de Vries et al., 2008; Lachiewicz et al., 2008; Balch et al.,
2009). We corrected P-values for multiple hypothesis testing using
the Benjamini–Hochberg method (Benjamini and Hochberg, 1995).
All statistical tests were two sided and were carried out using SAS
version 9.1 (SAS Institute, Cary, NC).
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